Physician profile
Kaley Prather
NPI 1023479516
$6,739.31
in general payments reported to CMS, 2019-2025
29 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $919 · 2022: $1,367 · 2023: $1,296 · 2024: $1,585 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,434 · Education: $19.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,434.08 |
| Education | $19.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,085.20 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,691.13 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $625.76 | 2021-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $319.54 | 2021-2025 | |
| Qol Medical, LLC | $302.18 | 2021-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $244.12 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $183.82 | 2022-2025 | |
| Celgene Corporation | $178.90 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $173.97 | 2021-2024 | Linzess |
| Gilead Sciences, INC. | $119.96 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.51 | 2021-2025 | Entyvio, Gattex |
| Nestle Healthcare Nutrition INC. | $89.04 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $75.10 | 2024-2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $70.40 | 2022 | |
| Lilly USA, LLC | $63.40 | 2024-2025 | Omvoh |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocon Biologics INC | $46.10 | 2025 | Yesintek |
| Madrigal Pharmaceuticals | $42.13 | 2024-2025 | Resmetirom, Rezdiffra |
| Phathom Pharmaceuticals, INC. | $41.67 | 2024-2025 | Voquezna |
| Mallinckrodt Hospital Products INC. | $41.19 | 2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $35.26 | 2022-2024 | Dificid |
| Braintree Laboratories, INC. | $32.24 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $31.21 | 2023-2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $30.65 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $21.28 | 2023 | Dupixent |
| Organon LLC | $20.46 | 2024 | |
| Celltrion USA INC. | $19.44 | 2024 | Zymfentra |
| Ardelyx, INC. | $19.00 | 2024 | Ibsrela |
| Amgen INC. | $15.21 | 2023 | Avsola, Amjevita |
| Endogastric Solutions, INC | $9.44 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaley Prather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.